JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

Начало・Списък с акции・Fulgent Genetics Inc

Fulgent Genetics Inc

Затворен

СекторЗдравеопазване

22.41 -0.53

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

22.69

Ключови измерители
By Trading Economics
Приходи	-7.4M -19M
Продажби	8.3M 82M
Марж на печалбата	-23.539
Служители	1,313
EBITDA	-3.5M -15M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+12.18% upside

Дивиденти
By Dow Jones
Следващи печалби	7.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	165M 713M
Предишно отваряне	22.94
Предишно затваряне	22.41

Настроения в новините

By Acuity

67%

33%

319 / 373 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

17.32 / 19.04 Подкрепа & съпротива

Fulgent Genetics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.10.2025 г., 17:40 ч. UTC

Придобивния, сливания и поглъщания

Orange to Buy Lorca's 50% Stake in MasOrange for $4.9 Billion

31.10.2025 г., 23:09 ч. UTC

Печалби

Review & Preview: October Surprise -- Barrons.com

31.10.2025 г., 22:44 ч. UTC

Придобивния, сливания и поглъщания

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

31.10.2025 г., 21:25 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Pfizer Says Novo Nordisk's Metsera Bid Won't Pass Antitrust Laws -- Market Talk

31.10.2025 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- Update

31.10.2025 г., 21:12 ч. UTC

Придобивния, сливания и поглъщания

Pfizer Sues Metsera, Novo Nordisk, Claiming Novo Nordisk Takeover Offer Isn't Superior -- WSJ

31.10.2025 г., 21:12 ч. UTC

Придобивния, сливания и поглъщания

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

31.10.2025 г., 21:12 ч. UTC

Придобивния, сливания и поглъщания

Pfizer Seeks Order Blocking Metsera From Terminating Its Merger Deal With Pfizer -- WSJ

31.10.2025 г., 20:51 ч. UTC

Придобивния, сливания и поглъщания

Another Rare-Earth Stock Jumps on Government Deal -- Barrons.com

31.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

31.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

31.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Auto & Transport Roundup: Market Talk

31.10.2025 г., 20:46 ч. UTC

Придобивния, сливания и поглъщания

Pfizer: Files Lawsuit Against Metsera and Its Directors and Novo Nordisk for Breach of Merger Agreement

31.10.2025 г., 20:22 ч. UTC

Печалби

Amazon Stock Hits New Record. What Was So Good in Its Earnings Report. -- Barrons.com

31.10.2025 г., 20:02 ч. UTC

Печалби

Meta Faces a Sudden Reckoning. How Big Tech Earnings Are Reshaping the AI Race. -- Barrons.com

31.10.2025 г., 19:55 ч. UTC

Пазарно говорене

Crude Futures Fall for Third Straight Month -- Market Talk

31.10.2025 г., 19:54 ч. UTC

Придобивния, сливания и поглъщания

Pfizer: FTC Granted Early Termination of Waiting Period >PFE

31.10.2025 г., 19:54 ч. UTC

Придобивния, сливания и поглъщания

Pfizer: Receives Early Clearance From FTC for Metsera Acquisition

31.10.2025 г., 19:26 ч. UTC

Пазарно говорене

U.S. Natural Gas Rises on Winter Outlook, Strong LNG -- Market Talk

31.10.2025 г., 18:30 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Amazon, Nvidia, Apple, Netflix, Exxon, DexCom, Coinbase, Reddit, Newell Brands, and More -- Barrons.com

31.10.2025 г., 18:23 ч. UTC

Пазарно говорене

Gold Edges Lower for the Day, Closes October Positive -- Market Talk

31.10.2025 г., 18:09 ч. UTC

Печалби

Bank of America Has a Game Plan to Catch Up to Its Peers. It's Time to Buy the Stock. -- Barrons.com

31.10.2025 г., 18:08 ч. UTC

Печалби

Bank of America Has a Game Plan to Catch Up to Its Peers. It's Time to Buy the Stock. -- Barrons.com

31.10.2025 г., 17:36 ч. UTC

Пазарно говорене

Grain Futures Shrug Off Stronger Dollar -- Market Talk

31.10.2025 г., 17:31 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls, Natural Gas Rig Count Rises -- Market Talk

31.10.2025 г., 17:16 ч. UTC

Придобивния, сливания и поглъщания

Orange: Acquisition Likely Completed in First Half Next Year

31.10.2025 г., 17:15 ч. UTC

Придобивния, сливания и поглъщания

Orange: Agreement Set to Be Signed By Year-Out

31.10.2025 г., 17:14 ч. UTC

Придобивния, сливания и поглъщания

Orange: Acquisition Will Strengthen Position in Spain

31.10.2025 г., 17:13 ч. UTC

Придобивния, сливания и поглъщания

Orange Will Be Sole Owner of Spain's MasOrange Following Acquisition of Lorca's Stake

31.10.2025 г., 17:12 ч. UTC

Придобивния, сливания и поглъщания

Orange Reaches Deal to Buy Lorca's 50% Stake in MasOrange for EUR4.25B

Сравнение с други в отрасъла

Ценова промяна

Fulgent Genetics Inc Прогноза

Ценова цел

By TipRanks

12.18% нагоре

12-месечна прогноза

Среден 25.33 USD 12.18%

Висок 30 USD

Нисък 21 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Fulgent Genetics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Fulgent Genetics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

17.32 / 19.04Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

The bullish and bearish events are balanced.

Настроение

By Acuity

319 / 373 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Fulgent Genetics Inc

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.